AACR VIRTUAL PATIENT ADVOCATE FORUM

PRECISION ONCOLOGY ADVANCES IN 2020-LOOKING AHEAD TO 2021!

SPEAKER BIOS

-IN ORDER OF APPEARANCE

ANTONI RIBAS, MD, PHD, FAACR
President, American Association for Cancer Research
Jonsson Comprehensive Cancer Center
University of California Los Angeles

Antoni Ribas, MD, PhD, is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA). He serves as director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and director of the Parker Institute for Cancer Immunotherapy Center at UCLA.

His research has focused on the use of immunotherapy to treat melanoma, the deadliest form of skin cancer. He led the clinical program that demonstrated the effectiveness of the immunotherapeutic pembrolizumab (Keytruda), which has been a significant advancement in the treatment of melanoma. Recent work includes laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor engineered lymphocytes; examining the antitumor activity of PD-1-blocking antibodies; testing novel targeted therapies blocking oncogenic events in melanoma; and studying primary and acquired resistance to melanoma therapies.

From 2001 to 2010, Dr. Ribas was the assistant director for Clinical Programs at the UCLA Human Gene Medicine Program. He led the Jonsson Cancer Center's Cell and Gene Therapy Core Facility from 2004 to 2010. Outside his roles at UCLA, he co-led the Stand Up to Cancer-Cancer Research Institute-AACR Immunotherapy Dream Team with Nobel Laureate James Allison.

Dr. Ribas has been a member of the AACR Board of Directors since 2016. In addition to his role as president, Ribas served as Program Chair for the AACR Annual Meeting 2020, the preeminent international meeting in cancer research. Due to the COVID-19 pandemic, the scientific program for the in-person meeting was adapted into two groundbreaking Virtual Annual Meetings under his innovative leadership, with more than 73,000 registered attendees from 127 countries around the world. To rapidly respond to the ongoing challenges of COVID-19, he formed an AACR COVID-19 and Cancer Task Force that includes experts from all the disciplines relevant to this disease and its impact on cancer.

ANNA D. BARKER, PHD
AACR Scientist↔Survivor Program®
Ellison Institute of Transformative Medicine
University of Southern California

Anna Barker, PhD is the Chief Strategy Officer at the Ellison Institute, where she is building networks of leading experts in medicine, science and engineering, that will help the Ellison Institute advance

scientific discoveries and innovations that solve complex problems in cancer and other diseases. Previously, Dr. Barker served as the principal deputy director of the National Cancer Institute (NCI) and deputy director for strategic scientific initiatives. In these roles she led the development of foundational platforms and national programs to support the emerging concept of precision medicine. During her tenure at the NCI, she collaboratively planned and implemented a number of strategic convergence programs that emphasized innovation, networks of global institutions, team science and publicly available data.

Initiatives and programs under Dr. Barker's leadership include: The Cancer Genome Atlas co-developed with the National Human Genome Research Institute the Biospecimens Research Network; the NCI Clinical Proteomics Technology in Cancer Initiative; the NCI Alliance for Nanotechnology in Cancer Program; and the Physical Sciences-Oncology Centers Program (which connects physicists, mathematicians, engineers and cancer scientists dedicated to developing a fundamental understanding of cancer), among several others. Additionally, Dr. Barker collaborated with the leadership of the FDA and was founding co-chair of the NCI-FDA Interagency Oncology Task Force, the Cancer Steering Committee of the Foundation for the NIH Biomarker Consortium and she led the NCI's international programs.

Most recently, Dr. Barker served as Director of Transformative Healthcare Networks, co-director of Complex Adaptive Systems -Biomedicine (CAS) and professor of practice, School of Life Sciences at Arizona State University (ASU). In these roles, she designed and implemented "knowledge network" models that address complex diseases such as cancer as complex adaptive systems. These systems approaches have been employed to create innovative solutions in areas such as biomarker discovery and development, new clinical trial designs, and the roles of big data and artificial intelligence in precision medicine. As a result of her efforts, she led the development of the biomarker and clinical trials sections of the 21 Century Cures Act.

BOB RITER, MHSA
AACR Scientist↔Survivor Program®
Physical Sciences Oncology Center
Cornell University

Bob Riter has been instrumental in developing a collaboration between cancer researchers at Cornell University and cancer patients/survivors in the Ithaca area. A particular focus of this collaboration is exposing doctoral students and post-docs in the basic sciences to the human side of cancer. Bob now serves as the Patient Advocate at Cornell University's Physical Sciences Oncology Center, and is increasingly active in patient advocacy on a national level. He served for more than 7 years as the executive director of the Cancer Resource Center of the Finger Lakes, an organization that provides support, information and community to people affected by cancer.

Bob's involvement with cancer support and education began in 1996 when he was diagnosed with breast cancer. Unlike many men with the disease, Bob decided to be public about his diagnosis and did it by writing an essay about his experiences that appeared in the July 17, 1997 issue of Newsweek Magazine. He later published the book, When Your Life is Touched by Cancer" offering practical advice and insights for patients, professionals, and those who care.

A native of Huntington, WV, Bob received his undergraduate degree from Oberlin College and a master's

degree in health services administration from the University of Michigan. Bob has been a member of the AACR Scientist↔Survivor Program® since 2018.

JOHN L. MARSHALL, MD

Center for the Cure of Gastrointestinal Cancer
Lombardi Comprehensive Cancer Center
Georgetown University

Dr. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials throughout his career. While he has an interest in many areas of cancer research, his primary focus is on the use of precision medicine in treating cancer.

Dr. Marshall has become an outspoken advocate for GI cancer patients and the importance of clinical research participation. In 2009, he established the Otto J Ruesch Center for the Cure of GI Cancers, an organization solely focused on improving the lives of GI cancer patients through innovative research, personalized medicine, and focused advocacy. In 2015, Dr. Marshall both established and directed the Precision Oncology Alliance, a national alliance established to study the impact of molecular profiling on cancer research, value and outcomes. He currently is serving as the Oncology CMO for Indivumed, creating a global precision medicine research network.

Dr. Marshall's passion for medicine began at an early age when, at 14, he lost his mother to non-Hodgkin lymphoma and dedicated himself to becoming a doctor and helping find a cure for cancer. A graduate of Duke University and the University of Louisville School of Medicine, he completed his medical training at Georgetown University Hospital and has remained there for over 20 years.

Dr. John Marshall's deep care for his patients and his warm humor help him to develop strong doctor-patient relationships. In 2006, he acquired the additional valuable perspective of being a caregiver for a cancer patient as his wife, Liza, was diagnosed with an aggressive form of breast cancer and underwent nine months of treatment. Dr. Marshall counts the relationships with his patients as one of the most gratifying parts of his job.

ELIZABETH M. JAFFEE, MD, FAACR

Past President, American Association for Cancer Research
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine

An internationally heralded expert in cancer immunology, Dr. Jaffee is well-regarded for her clinical studies that have fueled the development of immunotherapies, specifically allogeneic cancer vaccines. She has led numerous efforts and clinical trials dedicated to establishing effective vaccines for the treatment of not only unresectable breast and pancreatic cancers, but also cancers that are eligible for surgical resection, but present with a high likelihood of recurrence. These vaccines have been designed to bypass immunotolerance exhibited by tumors and have proven effective in improving disease-free survival in patients.

Specifically, Dr. Jaffee has contributed to the testing and development of the GVAX cancer vaccine for pancreatic cancer, which is designed to include allogeneic pancreatic cancer cells capable of secreting the immunostimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), normally produced by immune cells including T cells and natural killer cells. Dr. Jaffee has explored combinations

involving GVAX and the CRS-207 vaccine, composed of recombinant live-attenuated, double-deleted Listeria monocytogenes that are genetically modified to secrete the tumor-associated antigen, mesothelin. These studies have demonstrated that GVAX administration in combination with CRS-207 effectively combats pancreatic cancer progression and increases overall survival with low toxicity.

More recently, her research has been dedicated to exploiting genomic and proteomic technologies to define biomarkers required for pancreatic cancer onset and progression. These studies have resulted in the identification of ANXA2 (Annexin A2) as a potential regulator of pancreatic cancer metastasis. Dr. Jaffee and her colleagues have demonstrated that ANXA2 is overexpressed in pancreatic cancers and that this overexpression is accompanied by changes in intracellular trafficking of ANXA2. Furthermore, changes in the cellular location of ANXA2 directly correlate with the ability of pancreatic cancer cells to proliferate and migrate into adjacent organs such as the liver. Dr. Jaffee's ongoing efforts are dedicated to understanding how to integrate immune modulating agents with vaccines in both patients and animal models.

DAVID SPETZLER, MS, PHD, MBA
Caris Life Sciences

Dr. Spetzler joined Caris Life Sciences® in August of 2009, and has held several management positions with increasing responsibilities during his tenure. He leads the company's clinical testing service and development of proprietary technologies to aid in the creation of precision medicine strategies for individual cancer patients and noninvasive technologies to identify and predict early stage cancer. Using Caris Molecular Intelligence®, ADAPT Biotargeting System™, and DEAN™, an advanced AI platform focused on nonlinear feature selection to identify new biological signatures to improve cancer diagnosis and treatment selection, Dr. Spetzler has generated more than 330 patent applications across 37 different patent families and authored 31 peer-reviewed journal articles.

He is an innovator in molecular science with a relentless focus on improving patient care through an unwavering commitment to the highest quality, fastest turn-around-time and greatest scientific rigor to fulfill the promise of precision medicine. He has led the development of the company's exclusive and unique technology, ADAPT, which is able to measure thousands of protein aberrations and is being used to develop early cancer detection assays, discover novel drug targets, and characterize protein differences in each patient's tumor. During his tenure, Caris has amassed molecular data on 240,000+ patients and clinical outcomes on 215,000 patients since the launch of its molecular profiling service in 2009.

Dr. Spetzler led the development of the company's proprietary AI platform (DEAN) to create and validate dozens of machine learning signatures, called Next Generation Profiling™ (NGP), thus providing the most in-depth and exclusive analysis and interpretation using the most comprehensive suite of clinical offerings available to cancer patients today. The Company is preparing to launch and continues to develop dozens of unique proprietary AI DEAN-driven, machine learning signatures unlocked from a decade of testing patients and accumulating outcomes data to improve cancer diagnosis and therapeutic guidance never before seen.